MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--TYRX, Inc., a leader in the commercialization of implantable medical devices designed to help reduce surgical-site infections (SSIs) associated with cardiac implantable electronic devices (CIEDs), announced today that it has completed the site enrollment phase of its 50-site CITADEL & CENTURION studies to evaluate the company’s AIGISRx Antibacterial Envelope.
